Kravis Investment Partners
VC Fund
Kravis Investment Partners is a VC fund focused on Apps and Banking. Kravis Investment Partners
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Kravis Investment Partners invests in
Stages Kravis Investment Partners invests in
Countries Kravis Investment Partners invests in
Investment Focus
Industry
- Apps 1 (25%)
- Banking 1 (25%)
- FinTech 1 (25%)
- Finance 1 (25%)
- Health Care 1 (25%)
Stage
- Series C 2 (50%)
- Series B 1 (25%)
- Series D 1 (25%)
Country
- India 1 (25%)
- United States 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Stashfin
|
StashFin is a digital lending venture that offers online applications for personal loans, providing simple and fast approval and disbursal for loans. It was started by a team of former financial services professionals who have more than 40 years of experience in consumer finance and capital markets.It was founded in 2016 and headquartered in NewDelhi. | $70M / Series C / Jun 21, 2022 | |
|
Stashfin
|
StashFin is a digital lending venture that offers online applications for personal loans, providing simple and fast approval and disbursal for loans. It was started by a team of former financial services professionals who have more than 40 years of experience in consumer finance and capital markets.It was founded in 2016 and headquartered in NewDelhi. | $40M / Series B / Apr 02, 2021 | |
ORIC Pharmaceuticals
|
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate,ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeuticsacross a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments. | $55M / Series D / Aug 09, 2019 | |
|
ORIC Pharmaceuticals
|
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate,ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeuticsacross a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments. | $50M / Series C / Feb 21, 2018 |
Co-Investors
Altara Ventures
2 deals together
EcoR1 Capital
2 deals together
Foresite Capital
2 deals together
Memorial Sloan - Kettering Cancer Center
2 deals together
OrbiMed
2 deals together
Snow Leopard Technology Ventures
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Kravis Investment Partners invest in?
Kravis Investment Partners invests primarily in Apps, Banking and FinTech startups, most often at Series C and Series B stage. Most of the 4 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Kravis Investment Partners last invest?
The most recent investment recorded for Kravis Investment Partners closed in Jun 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
